Nasal pharmaceutical formulations and methods of using the same
AssigneeMylan Specialty L.P.
InventorImtiaz Chaudry
Life of this patent
Estimating the term…
Abstract
Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific particle size distribution profile. In a preferred embodiment, the corticosteroid is fluticasone or a pharmaceutically acceptable derivative thereof for the treatment of one or more symptoms of rhinitis. Preferably, the drug substance is fluticasone propionate. The formulations herein may be provided as an aqueous suspension suitable for inhalation via the intranasal route.
Claims17
A nasal pharmaceutical formulation comprising an aqueous suspension of a therapeutically effective amount of fluticasone propionate, wherein the aqueous suspension comprises 0.04% to 0.06% by weight of suspended solid fluticasone propionate particles having the following particle size distribution profile:
- about 10% of the solid fluticasone particles have a particle size of less than 0.4 microns;
- about 25% of the solid fluticasone particles have a particle size of less than 0.75 microns;
- about 50% of the solid fluticasone particles have a particle size of less than 1.5 microns;
- about 75% of the solid fluticasone particles have a particle size of less than 3.0 microns;
- and
- about 90% of the solid fluticasone particles have a particle size of less than 5.3 microns;
- wherein the fluticasone is suitable for administration to an individual intranasally,
- wherein the formulation further comprises a complexing agent selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), citric acid, nitrilotriacetic acid, and salts thereof,
- and wherein greater than 95% of the fluticasone originally present in the formulation remains in the formulation after storage for 12 months at a temperature between 15 to 30° C.;
- and
- wherein the formulation further comprises the following compounds:
- (a) microcrystalline cellulose;
- (b) carboxymethyl cellulose sodium;
- (c) dextrose;
- (d) benzalkonium chloride;
- (e) polysorbate 80;
- and
- (f) phenylethyl alcohol;
- wherein the formulation further comprises zinc chloride;
- and
- wherein the formulation is sterile.
A system for the treatment of one or more symptoms of rhinitis, said system comprising:
- (a) a pre-packaged formulation, said formulation comprising an aqueous suspension comprising about 0.04% to 0.06% by weight of suspended solid fluticasone propionate particles, wherein the suspended solid fluticasone propionate particles have the following particle size distribution profile:
- (i) about 10% of the solid fluticasone particles have a particle size of less than 0.4 microns;
- (ii) about 25% of the solid fluticasone particles have a particle size of less than 0.75 microns;
- (iii) about 50% of the solid fluticasone particles have a particle size of less than 1.5 microns;
- (iv) about 75% of the solid fluticasone particles have a particle size of less than 3.0 microns;
- and
- (v) about 90% of the solid fluticasone particles have a particle size of less than 5.3 microns;
- wherein the fluticasone is suitable for administration to an individual intranasally,
- wherein the formulation further comprises a complexing agent selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), citric acid, nitrilotriacetic acid, and salts thereof,
- wherein greater than 95% of the fluticasone originally present in the formulation still remains in the formulation after storage for 12 months at a temperature between 15 to 30° C.;
- wherein the formulation further comprises the following compounds:
- (a) microcrystalline cellulose;
- (b) carboxymethyl cellulose sodium;
- (c) dextrose;
- (d) benzalkonium chloride;
- (e) polysorbate 80;
- and
- (f) phenylethyl alcohol;
- wherein the formulation further comprises zinc chloride;
- and
- wherein the formulation is sterile.
An aqueous nasal spray formulation comprising an aqueous suspension of 0.04% to 0.06% by weight of suspended solid fluticasone propionate particles, wherein the aqueous suspension has the following suspended solid particle size distribution profile:
- about 10% of the solid fluticasone particles have a particle size of less than 0.4 microns;
- about 25% of the solid fluticasone particles have a particle size of less than 0.75 microns;
- about 50% of the solid fluticasone particles have a particle size of less than 1.5 microns;
- about 75% of the solid fluticasone particles have a particle size of less than 3.0 microns;
- and
- about 90% of the solid fluticasone particles have a particle size of less than 5.3 microns;
- wherein the fluticasone is suitable for administration to an individual intranasally,
- wherein the formulation further comprises a complexing agent selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), citric acid, nitrilotriacetic acid, and salts thereof,
- wherein greater than 95% of the fluticasone originally present in the formulation still remains in the formulation after storage for 12 months at a temperature between 15 to 30° C.;
- wherein the formulation further comprises the following compounds:
- (a) microcrystalline cellulose;
- (b) carboxymethyl cellulose sodium;
- (c) dextrose;
- (d) benzalkonium chloride;
- (e) polysorbate 80;
- and
- (f) phenylethyl alcohol;
- wherein the formulation further comprises zinc chloride;
- and
- wherein the nasal spray formulation is sterile.
An aqueous nasal spray formulation comprising:
- an aqueous suspension of suspended solid fluticasone propionate particles;
- wherein the formulation comprises 0.04% to 0.06% by weight of fluticasone propionate particles having the following solid particle size distribution profile:
- D10 is 0.39 microns;
- D25 is 0.76 microns;
- D50 is 1.52 microns;
- D75 is 2.97 microns;
- and
- D90 is 5.28 microns,
- wherein the formulation further comprises a complexing agent selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), citric acid, nitrilotriacetic acid, and salts thereof,
- wherein greater than 95% of the fluticasone originally present in the formulation still remains in the after storage for 12 months at a temperature between 15 to 30° C.;
- wherein the nasal spray formulation further comprises the following compounds:
- (a) microcrystalline cellulose;
- (b) carboxymethyl cellulose sodium;
- (c) dextrose;
- (d) benzalkonium chloride;
- (e) polysorbate 80;
- and
- (f) phenylethyl alcohol;
- wherein the formulation further comprises zinc chloride;
- and
- wherein the nasal spray formulation is sterile.
Dependencies are inferred from the claim text.